Prenetics Global Ltd
PRE Nasdaq Pharmaceutical Preparations Financials FY2020โFY2025
Revenue
Total sales reported in the income statement.
$92.4M
479.8%
vs prior year
Operating margin
Operating income as a share of revenue.
โ48.1%
179.5ย pts
Net income
Profit after all expenses, interest and tax.
โ$37.7M
Free cash flow
Cash from operations minus capital spending.
โ$22.0M
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
โ
Market cap
Last close times the latest diluted share count, so it is approximate.
โ
P/E
Last close divided by diluted earnings per share over the last four quarters.
โ
On โ$2.68 EPS (TTM)
What Prenetics Global Ltd does
No business description yet.
- Legal name
- Prenetics Global Ltd
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F ยท Apr 30, 2026
- Accession ยท CIK
- 0001628280-26-028623
0001876431
Revenue and margins
Prenetics Global Ltd had $92.4M of revenue in fiscal 2025, up 479.8% on the year before.
FY20
Revenue $65.2M
FY21
Revenue $12.5M
FY22
Revenue $13.2M
FY23
Revenue $21.7M
FY24
Revenue $15.9M
FY25
Revenue $92.4M
FY20
Gross 40.4%
Operating โ1.5%
Net โ3.0%
FCF โ8.8%
FY21
Gross 28.7%
Operating โ452.1%
Net โ1,388.4%
FCF 38.9%
FY22
Gross 27.5%
Operating โ501.5%
Net โ1,446.8%
FCF 72.7%
FY23
Gross 5.4%
Operating โ176.8%
Net โ288.5%
FCF โ64.9%
FY24
Gross 58.2%
Operating โ227.6%
Net โ290.6%
FCF โ187.5%
FY25
Gross 52.8%
Operating โ48.1%
Net โ40.8%
FCF โ23.8%
Gross
Operating
Net
FCF
Net income and earnings per share
Loss periods are shown in red.
FY20
Net income โ$1.9M
FY21
Net income โ$174M
FY22
Net income โ$190M
FY23
Net income โ$62.7M
FY24
Net income โ$46.3M
FY25
Net income โ$37.7M
FY20
Diluted EPS โ$0.15
FY21
Diluted EPS โ$178.81
FY22
Diluted EPS โ$37.57
FY23
Diluted EPS โ$5.58
FY24
Diluted EPS โ$3.71
FY25
Diluted EPS โ$2.68
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY20
Return on capital โ
Return on equity โ6.3%
Return on assets โ
FY21
Return on capital โ
Return on equity โ
Return on assets โ117.2%
FY22
Return on capital โ
Return on equity โ
Return on assets โ82.7%
FY23
Return on capital โ
Return on equity โ28.3%
Return on assets โ22.2%
FY24
Return on capital โ
Return on equity โ24.6%
Return on assets โ19.8%
FY25
Return on capital โ
Return on equity โ23.1%
Return on assets โ18.0%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was โ$22.0M in fiscal 2025, โ23.8% of revenue. Cash from operations minus capital spending.
FY20
Free cash flow โ$5.7M
FY21
Free cash flow $4.9M
FY22
Free cash flow $9.6M
FY23
Free cash flow โ$14.1M
FY24
Free cash flow โ$29.9M
FY25
Free cash flow โ$22.0M
FY20
Cash from operations โ$2.9M
Capital spending $2.9M
FY21
Cash from operations $13.4M
Capital spending $8.5M
FY22
Cash from operations $14.5M
Capital spending $4.9M
FY23
Cash from operations โ$13.8M
Capital spending $0.3M
FY24
Cash from operations โ$28.9M
Capital spending $1.0M
FY25
Cash from operations โ$21.8M
Capital spending $0.2M
Cash from operations
Capital spending
Dividends, buybacks and share count
Prenetics Global Ltd returned โ to shareholders in fiscal 2025. The diluted share count rose 12.5%.
FY20
Dividends โ
Buybacks โ
FY21
Dividends โ
Buybacks โ
FY22
Dividends โ
Buybacks โ
FY23
Dividends โ
Buybacks โ
FY24
Dividends โ
Buybacks โ
FY25
Dividends โ
Buybacks โ
Dividends
Buybacks
FY20
Diluted shares 0.01B
FY21
Diluted shares 0.00B
FY22
Diluted shares 0.01B
FY23
Diluted shares 0.01B
FY24
Diluted shares 0.01B
FY25
Diluted shares 0.01B
Balance sheet
Cash, debt and the ratios that show how comfortably Prenetics Global Ltd can carry it.
FY20
Cash $14.5M
Debt โ
FY21
Cash $35.3M
Debt โ
FY22
Cash $147M
Debt โ
FY23
Cash $45.7M
Debt โ
FY24
Cash $52.3M
Debt โ
FY25
Cash $32.1M
Debt โ
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $35.3M | $147M | $45.7M | $52.3M | $32.1M |
| Interest coverage | โ10.8x | โ15.7x | โ | โ | โ |
| Current ratio | 1.8x | 4.2x | 2.4x | 2.4x | 3.0x |
| Quick ratio | 1.7x | 4.1x | 2.3x | 2.2x | 2.7x |
| Total assets | $149M | $312M | $254M | $214M | $206M |
| Total liabilities | $549M | $68.7M | $44.0M | $42.2M | $49.7M |
| Shareholders' equity | โ$401M | $237M | $206M | $170M | $156M |
| Net debt (โ = net cash) | โ | โ | โ | โ | โ |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โPlanโ marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
โ
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8โ9 is strong, 0โ2 weak.
| Test | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Net income is positive | โ | โ | โ | โ | โ | โ |
| Cash from operations is positive | โ | โ | โ | โ | โ | โ |
| Return on assets rose | โ | โ | โ | โ | โ | โ |
| Cash from operations exceeds net income | โ | โ | โ | โ | โ | โ |
| Debt fell relative to assets | โ | โ | โ | โ | โ | โ |
| Current ratio rose | โ | โ | โ | โ | โ | โ |
| Share count didn't rise | โ | โ | โ | โ | โ | โ |
| Gross margin rose | โ | โ | โ | โ | โ | โ |
| Revenue rose relative to assets | โ | โ | โ | โ | โ | โ |
| F-score | โ / 3 | โ / 5 | 4 / 8 | 3 / 8 | 3 / 8 | 4 / 8 |
| Accruals ratio | โ | โ126.2% | โ89.0% | โ17.3% | โ7.5% | โ7.6% |
| Altman Z'' | โ | โ | โ | โ | โ | โ |
6 years of figures
Amounts in USD. Hover a ratioโs name for its definition.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $65.2M | $12.5M | $13.2M | $21.7M | $15.9M | $92.4M |
| Gross profit | $26.3M | $3.6M | $3.6M | $1.2M | $9.3M | $48.8M |
| Research and development | $2.8M | $6.4M | $6.0M | $9.2M | $9.1M | $5.1M |
| Operating income | โ$1.0M | โ$56.7M | โ$66.0M | โ$38.4M | โ$36.3M | โ$44.5M |
| Interest expense | $0.1M | $5.2M | $4.2M | โ | โ | โ |
| Pretax income | โ$3.9M | โ$217M | โ$226M | โ$42.9M | โ$46.0M | โ$36.2M |
| Income tax | โ$1.9M | $2.6M | โ$0.2M | $0.1M | โ$7.6M | $0.0M |
| Net income | โ$1.9M | โ$174M | โ$190M | โ$62.7M | โ$46.3M | โ$37.7M |
| Net income to common | โ$1.9M | โ$174M | โ$190M | โ$62.7M | โ$46.3M | โ$37.7M |
| Diluted EPS | โ$0.15 | โ$178.81 | โ$37.57 | โ$5.58 | โ$3.71 | โ$2.68 |
| Diluted shares | 0.01B | 0.00B | 0.01B | 0.01B | 0.01B | 0.01B |
| Cash flow | ||||||
| Cash from operations | โ$2.9M | $13.4M | $14.5M | โ$13.8M | โ$28.9M | โ$21.8M |
| Capital expenditure | $2.9M | $8.5M | $4.9M | $0.3M | $1.0M | $0.2M |
| Free cash flow | โ$5.7M | $4.9M | $9.6M | โ$14.1M | โ$29.9M | โ$22.0M |
| Stock-based compensation | $1.6M | $22.5M | $31.6M | $10.6M | $7.8M | $7.6M |
| Acquisitions | $2.9M | $0.0M | $3.4M | $0.0M | $8.3M | $0.0M |
| Balance sheet | ||||||
| Cash and short-term investments | $14.5M | $35.3M | $147M | $45.7M | $52.3M | $32.1M |
| Current assets | โ | $107M | $242M | $93.7M | $86.1M | $85.2M |
| Current liabilities | โ | $58.7M | $57.2M | $39.5M | $36.6M | $28.7M |
| Inventory | โ | $6.8M | $4.5M | $3.1M | $6.6M | $7.0M |
| Property and equipment, net | โ | $13.0M | $13.1M | โ | โ | โ |
| Goodwill | $4.0M | $4.0M | $33.8M | $29.2M | $37.4M | $1.4M |
| Intangible assets | โ | $23.8M | $14.8M | $13.4M | $11.6M | $0.1M |
| Total assets | โ | $149M | $312M | $254M | $214M | $206M |
| Total liabilities | โ | $549M | $68.7M | $44.0M | $42.2M | $49.7M |
| Shareholders' equity | $31.0M | โ$401M | $237M | $206M | $170M | $156M |
| Margins | ||||||
| Gross margin | 40.4% | 28.7% | 27.5% | 5.4% | 58.2% | 52.8% |
| Operating margin | โ1.5% | โ452.1% | โ501.5% | โ176.8% | โ227.6% | โ48.1% |
| Net margin | โ3.0% | โ1,388.4% | โ1,446.8% | โ288.5% | โ290.6% | โ40.8% |
| FCF margin | โ8.8% | 38.9% | 72.7% | โ64.9% | โ187.5% | โ23.8% |
| Returns | ||||||
| Return on capital employed | โ | โ63.1% | โ25.9% | โ17.9% | โ20.5% | โ25.1% |
| Return on equity | โ6.3% | โ | โ | โ28.3% | โ24.6% | โ23.1% |
| Return on assets | โ | โ117.2% | โ82.7% | โ22.2% | โ19.8% | โ18.0% |
| Return on tangible equity | โ7.2% | โ | โ101.0% | โ38.3% | โ38.1% | โ24.3% |
| Growth | ||||||
| Revenue growth | โ | โ80.8% | 5.0% | 65.2% | โ26.7% | 479.8% |
| FCF growth | โ | โ | 96.5% | โ247.5% | โ | โ |
| Share count change | โ | โ92.6% | 420.9% | 121.8% | 11.1% | 12.5% |
| Financial health | ||||||
| Interest coverage | โ16.7x | โ10.8x | โ15.7x | โ | โ | โ |
| Current ratio | โ | 1.8x | 4.2x | 2.4x | 2.4x | 3.0x |
| Quick ratio | โ | 1.7x | 4.1x | 2.3x | 2.2x | 2.7x |
| Capital allocation | ||||||
| Capex / revenue | 4.4% | 68.2% | 37.6% | 1.6% | 6.3% | 0.2% |
| Stock comp / revenue | 2.5% | 179.5% | 239.9% | 48.7% | 49.2% | 8.2% |
| Quality scores | ||||||
| Piotroski F-score | โ | โ | 4.0 | 3.0 | 3.0 | 4.0 |
| Accruals ratio | โ | โ126.2% | โ89.0% | โ17.3% | โ7.5% | โ7.6% |
Source: SEC EDGAR XBRL filings (CIK 0001876431). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ not investment advice. Check the original filings before relying on any figure.